ALXO ALX ONCOLOGY HOLDINGS INC

Nasdaq alxoncology.com


$ 1.65 $ 0.15 (10 %)    

Monday, 20-Oct-2025 15:59:54 EDT
QQQ $ 611.85 $ 7.61 (1.26 %)
DIA $ 467.41 $ 5.24 (1.13 %)
SPY $ 671.60 $ 6.91 (1.04 %)
TLT $ 91.67 $ 0.35 (0.38 %)
GLD $ 401.45 $ 14.16 (3.64 %)
$ 1.65
$ 1.55
$ 1.65 x 200
$ 1.70 x 18
$ 1.55 - $ 1.67
$ 0.40 - $ 2.27
412,030
na
88.36M
$ 1.53
$ 4.83
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-07-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-18-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-27-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 alx-oncology-announces-first-patient-dosed-in-phase-1-clinical-trial-for-alx2004-egfr-adc-that-is-being-studied-for-treatment-of-egfr-expressing-solid-tumors

- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004...

 alx-oncology-holdings-q2-adj-eps-044-beats-045-estimate

ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of...

 ubs-maintains-buy-on-alx-oncology-holdings-lowers-price-target-to-1

UBS analyst Colin Bristow maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and lowers the price target from $1.2 to $1.

 alx-oncology-unveils-clinical-development-plans-for-alx2004-a-adc-targeting-egfr-expressing-tumors-with-phase-1-trials-set-for-mid-2025-following-fda-ind-clearance-and-initial-data-expected-in-1h-2026-while-advancing-cd47-blocker-evorpacept-in-breast-and-colorectal-cancer-trials-also-starting-mid-2025

- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004...

 hc-wainwright--co-maintains-buy-on-alx-oncology-holdings-lowers-price-target-to-2

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and lowers t...

 alx-oncology-holdings-q1-adj-eps-048-misses-046-estimate

ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate ...

 alx-oncology-announces-final-results-from-phase-1-trial-evaluating-evorpacept-in-combination-with-standard-of-care-treatment-in-patients-with-b-cell-non-hodgkin-lymphoma--combination-generated-complete-responses-in-83-of-patients-with-indolent-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma

Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, ev...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION